Dietary iron intake, body iron stores, and the risk of type 2 diabetes: a systematic review and meta-analysis

We identified relevant articles by a systematic search of the MEDLINE/PubMed and EMBASE databases to the end of 22 April 2012, using a combination of free text and subheadings from MeSH or EMTREE terms. The following terms were used for the MEDLINE search: ("Diabetes Mellitus/epidemiology"[Mesh] or "Hyperglycemia/epidemiology"[Mesh] or "Diabetes Mellitus, Type 2"[Mesh] or type 2 diabet*[tiab] or non-insulin dependent diabet*[tiab]) and (iron intake or iron consumption or heme iron[tiab] or iron store*[tiab] or iron status[tiab] or "Ferritins"[Mesh] or ferritin[tiab]) not (review[pt] or editorial[pt]). Similar search terms were used for the EMBASE database. In addition, the references listed in any relevant original papers and review articles were screened. No language restriction was applied for searching or study inclusion.

Two investigators (WB and YR) independently evaluated the eligibility of all retrieved studies and extracted all relevant data using a standardized data extraction form. Any discrepancies were reconciled by consensus. A published article was included if it: 1) had a prospective cohort design, 2) evaluated the association between iron intake or body iron stores and risk of T2DM, and 3) reported the risk estimates and corresponding 95% confidence intervals (CIs) or standard errors. The process of study selection is depicted in Figure 1.

During the screening steps, several types of articles were excluded: review articles, editorials, or protocols; studies on animals or cell lines; studies that did not report iron intake or body iron stores as exposure; and studies that did not include T2DM as the outcome. In addition, studies that did not reported risk estimates or 95% CIs for the relationships between iron intake or body iron stores and risk of T2DM were excluded. One study was further excluded because data were not separately reported for T2DM [12].

For each included article, we extracted the following data: basic information (title, author, publication year, journal name), study characteristics (name of the study, study design, country, duration of follow-up), participant characteristics (sample size, number of T2DM cases, age, gender, race/ethnicity), assessment of iron intakes and body iron stores, ascertainment of T2DM, statistical methods used for the analysis, comparison, risk estimates and 95% CIs, and any covariates that were matched or adjusted for in the multivariate analysis.

If risk estimates were reported in several multivariate-adjusted models in the original studies, the one reported in the most fully-adjusted model (for example, for studies using iron intake as the exposure, we picked the model including other dietary factors as covariates) were extracted. Because circulating ferritin may be influenced by inflammation [26], we used a slightly different approach for studies that used ferritin as the indicator of body iron stores; we separately extracted the risk estimates from the most fully-adjusted models except for other biomarkers, and the models with additional adjustment for inflammation markers (such as C-reactive protein, interleukin-6, or fibrinogen). If available, we also extracted risk estimates from the models that also adjusted for other metabolic biomarkers (such as high-density lipoprotein cholesterol, triglycerides, fasting plasma glucose, fasting plasma insulin, glycated hemoglobin, homeostasis model assessment of insulin resistance, alanine aminotransferase, γ-glutamyltransferase, and adiponectin).

Relative risk (RR), odds ratio (OR) and hazard ratio (HR) were reported as the measures of association in the included studies. Because the incidence of T2DM was sufficiently low for the rare disease assumption (<10%) to apply, the OR was assumed to approximate the RR in each case, and thus we combined the ORs with the HRs and RRs in the meta-analysis.

The RRs and corresponding 95% CIs were pooled using the random-effects model (DerSimonian-Laird method), which incorporates between-study heterogeneity in addition to sampling variation [27]. To model a dose-response trend over dietary iron intakes in association with T2DM risk, we used the method proposed by Greenland and Longnecker [28] and the publicly available Stata code written by Orsini et al. [29]. The dose-response results in the forest plots are presented for a daily increment of 5 mg of dietary total iron intake and a daily increment of 1 mg of heme iron intake. Because the required data for a dose-response analysis were not available in most studies of body iron stores, we did not model a dose-response trend for the association between body iron stores and T2DM risk.

Two methods were used to assess heterogeneity across studies: the χ²-based Cochran's Q statistic (P<0.10 was considered to be significant heterogeneity), and the I ² metric (I ² values of 25%, 50%, and 75% were considered as low, medium, and high heterogeneity, respectively) [30]. Funnel plots were used to assess small-study effects. The possibility of publication bias was assessed using the Egger regression asymmetry test [31]. For sensitivity analysis, we also used the fixed-effects model for all the above analyses. Additional sensitivity analyses were performed by omitting one study at a time and calculating a pooled estimate for the remainder of the studies to evaluate whether the results were affected markedly by a single study.

All statistical analyses were performed using Stata software (version 11.2; Stata Corp, College Station, TX, USA). All P-values presented are two-tailed with a significance level of 0.05, except for the Cochran's Q statistic in the heterogeneity test, in which the significance level was 0.10 [30].

We identified 449 potentially relevant articles from PubMed/MEDLINE and EMBASE databases, of which 11 prospective studies [9‐11, 15‐17, 20, 21, 23, 24, 32] that met our inclusion criteria were finally included in this study. Five studies examined iron intake and risk of T2DM, while the other six assessed body iron stores and risk of T2DM.

Of the five studies that assessed iron intake and risk of T2DM [20, 21, 23, 24, 32], four were conducted in the USA and one in China. Participants were women only in three studies, men only in one study, and both women and men in one study. For assessment of iron intake, previously validated food frequency questionnaires were used in four studies, and a 3-day weighed food record method was used in the remaining study. Ascertainment of T2DM was based on self-report, plasma glucose measurements, or a combination of the two (Table 1).

Of the six studies that examined the association between body iron stores and risk of T2DM [9‐11, 15‐17], four were undertaken in the USA, one in the UK, and one in Finland. One was carried out with women only, one with men only and four with both. The indicator for body iron stores was ferritin in five studies, soluble transferrin receptor (sTfR) in one study, and the ratio of sTfR to ferritin in two studies. T2DM was ascertained using plasma glucose measurements in one study, and a combination of self-reported information and plasma glucose measurements in the remaining five studies (Table 1).

Associations between dietary intakes of total iron, heme iron, and non-heme iron and risk of T2DM were reported in three studies [20, 21, 23], five studies [20, 21, 23, 24, 32] and one study [24], respectively (Table 2). In the Iowa Women's Health Study [24], dietary total iron intake was largely reflective of non-heme iron intake (r = 0.995) and was not further analyzed, thus we derived the RR for association between dietary total iron intake and T2DM risk by pooling RRs of non-heme iron intake and heme iron intake in this study.

A meta-analysis of five studies showed that higher intake of heme iron was associated with a significantly greater risk of T2DM. The pooled RR (95% CI) in individuals with the highest level of heme iron intake compared with those with the lowest levels was 1.33 (1.19 to 1.48, P<0.001) for T2DM (Figure 2). However, no significant association was seen between dietary total iron intake and risk of T2DM; the pooled RRs and 95% CIs comparing the highest with the lowest levels of dietary total iron intake was 1.06 (0.98 to 1.14, P = 0.18) (Figure 2). There was no evidence for significant heterogeneity (heme iron intake: P = 0.24 (Q statistic), I ² = 27%; dietary total iron intake: P = 0.68 (Q statistic), I ² = 0%) or publication bias (heme iron intake, P = 0.08 (Egger test); dietary total iron intake, P = 0.06 (Egger test)) across the included studies (see Additional file 1, Figure S1).

In the dose-response analyses (Figure 3), the pooled RRs of T2DM were 1.16 (1.09 to 1.23, P<0.001) for a 1 mg/day increment of heme iron intake, with no evidence of heterogeneity (I² = 36%, P = 0.21), and 1.01 (0.99 to 1.03) for each 5 mg/day increment of dietary total iron intake, with no evidence of heterogeneity (I² = 0%, P = 0.90).

Sensitivity analyses using a fixed-effects model yielded similar results, and omitting one study at a time did not substantially alter the pooled results. In addition, two studies reported associations between supplemental iron intake and risk of T2DM [21, 24], and one study reported an association between the sum of dietary iron intake and supplemental iron intake and risk of T2DM [21]. However, neither of these studies found a significant association between supplemental iron or the summed iron intake and the risk of T2DM.

A significant association between body iron stores and risk of T2DM was seen in three [10, 11, 16] of the five studies that used ferritin as the indicator, and in all studies that used the sTfR:ferritin atio [9, 10] or the sTfR [17] alone as the indicator (Table 3).

For the meta-analysis of studies using ferritin as the indicator, the pooled RR (95% CI) for T2DM was 1.70 (1.27 o 2.27, P<0.001) for individuals with the highest ferritin levels, compared with those with the lowest (Figure 4). In the heterogeneity test, there was greater variation (moderate to high) in the study results than would be expected as a result of chance (P = 0.06 (Q statistic), I ² = 50%), which is not surprising given the substantial differences in study populations and methods. No evidence of publication bias was found (see Additional file 1, Figure S2A, P = 0.49 (Egger test)). Sensitivity analyses using fixed-effect model or omitting one study at a time did not substantially alter the pooled results.

Because measurement of circulating ferritin levels may be confounded by inflammation [26], we performed additional meta-analysis of the studies that reported RRs in multivariate-adjusted models with additional adjustment for inflammatory markers. The pooled RR (95% CI) for T2DM was 1.63 (1.03 to 2.56, P = 0.04) comparing individuals with the extreme categories (Figure 3). The heterogeneity across studies was high (P = 0.01 (Q statistic), I ² = 69%), which might be explained by the inclusion of other metabolic markers that could be biological intermediates in the multivariate models of several studies [15, 17]. A stratification analysis showed that the pooled RRs (95% CI) for T2DM were 2.24 (1.63 to 3.09) and 1.07 (0.56 to 2.05) for studies without and with other metabolic markers in the models, respectively. No evidence of publication bias was seen (P = 0.93 (Egger test) (see Additional file 1, Figure S2B)). Sensitivity analyses using a fixed-effects model yielded similar results, and omitting one study at a time did not substantially alter the magnitude of association, except for the omission of the study by Jehn et al. [15] (the pooled RR (95% CI) of the remaining studies was 2.06 (1.55 to 2.74)).

In this study, we found that heme iron intake and body iron stores were positively associated with an increased risk of T2DM, after adjustment for known potential confounders. Although dietary total iron intake has been associated with prevalent T2DM in a cross-sectional study [18], our meta-analysis of prospective studies found no significant association of dietary intakes of total iron, non-heme, and supplemental iron intake with the risk of T2DM. The positive association we found between heme iron and T2DM was consistent with previous results from prospective studies evaluating the relationships between red meat (the major source of heme iron) and the risk of T2DM [33, 34]. Because heme iron intake was found to be associated with higher body iron stores in previous studies [35, 36], our results suggest that high levels of body iron stores may mediate the association of increased risk of T2DM with chronically high heme iron intake.

The positive association between excess iron and risk of T2DM is biologically plausible, although the underlying mechanisms still remain to be fully determined. First of all, iron is a powerful pro-oxidant and catalyst that promotes the formation of hydroxyl radicals, which may attack pancreatic beta cells through increasing oxidative stress and thus result in impaired insulin synthesis and excretion [37]. Antioxidant enzymes, such as superoxide dismutase, catalase, and glutathione peroxidase, are expressed less in pancreatic islets than in other tissues, thus pancreatic islets are particularly susceptible to oxidative damage [3]. In a mouse model of hemochromatosis, excess iron resulted in beta-cell oxidant stress and decreased insulin secretory capacity secondary to beta-cell apoptosis and desensitization of glucose-induced insulin secretion [38]. Another study showed that even at 'normal' levels, iron exerted detrimental effects on pancreatic beta-cell function, and that these effects were reversible with dietary restriction or iron-chelation therapy [5]. Second, excess iron may diminish glucose utilization in muscle tissue and lead to a shift from glucose to fatty acid oxidation, which may result in increased insulin resistance. In a recent study using a mouse model of hemochromatosis, although glucose uptake was increased in skeletal muscle, glucose oxidation was decreased and the ratio of fatty acid to glucose oxidation was increased, as a result of decreased pyruvate dehydrogenase (PDH) enzyme activity and increased expression of PDH kinase 4 [39]. Third, increased substrate recycling to the liver may contribute to the higher hepatic glucose production [39].

Heme iron exists only in meat and meat products, where it occurs in the form of hemoglobin and myoglobin, whereas non-heme iron is present in both plant and animal foods [40]. The regulation of the intestinal iron absorption is crucial because there is no physiologic mechanism for excretion of iron [1]. Although heme iron is not the predominant form of dietary iron, it more readily absorbed than non-heme iron [2]. In addition, absorption of heme iron does not change with increasing dose, is less substantially affected by iron status than non-heme iron, and is not greatly influenced by other components in diet [35, 40]. Therefore, heme iron contributes about 50% of the total bioavailable iron in the typical western diet [20]. In an elderly population of the Framingham Heart Study, non-heme iron was the major source (mean 93%) of iron, yet heme iron intake was significantly and positively associated with serum ferritin concentration, whereas non-heme iron intake did not significantly influence serum ferritin concentration [35]. Similar positive association between heme iron intake and serum ferritin concentration was reported from the Health Professionals' Follow-up Study [41]. Therefore, the distinct effects of heme iron and non-heme iron intake on risk of T2DM that we found in the present study may be, at least partly, explained by the differences in bioavailability of the different iron types and their effects on body iron stores.

Circulating ferritin, a major iron storage protein in body, has been widely used as an index of body iron stores [26]. However, the specificity of high circulating ferritin levels as a marker of increased body iron stores is somewhat limited because ferritin is an acute-phase reactant [2], and circulating ferritin is increased in the presence of inflammation and other disorders [26, 42]. In addition, circulating ferritin is also increased with alcohol consumption and body mass index (BMI), and differs with gender [35, 36]. In our meta-analysis, even though we adjusted for alcohol consumption, BMI, gender, inflammation and other factors, the association between ferritin and risk of T2DM remained significant. In addition, the sTfR:ferritin ratio has been found to distinguish between subjects with similarly high ferritin levels, and sTfR is believed to be free of influence by acute or chronic inflammation, therefore it has been suggested that the sTfR:ferritin ratio is a better marker than ferritin alone to measure a wide range of iron levels [43]. Thus far, two prospective studies using the sTfR:ferritin ratio as a marker of body iron stores found similar significant associations [9, 10]. Use of phlebotomy or iron-chelation therapy to reduce ferritin levels was associated with improved glucose tolerance in patients with HH [44, 45], healthy blood donors [46], patients with metabolic syndrome [47], and patients with T2DM [48]. These studies support our findings of a significant association between increased body iron stores and T2DM risk.

The strengths of our study include the use of prospective studies with long-term follow-up, large sample size, and extensive adjustment for potential confounders, which together reduce the possibility of selection bias and reverse causation. However, several limitations need to be addressed. First, genetic polymorphisms (for example, H63D and C282Y variants in the HFE gene, which contributes to the development of HH) may affect the efficiency of iron absorption and body iron stores [40]. A potential interaction between HFE genotypes and heme iron intake in relation to the risk of T2DM has been reported in a previous study [49]. However, the allele frequencies of HFE variants are very low in the general population [49] and thus there is a low likelihood that they would have substantially affected the observed associations in the present study. In addition, our previous studies found that microsatellite polymorphism in the heme oxygenase-1 gene (HO-1), which encodes the rate-limiting enzyme in heme iron catabolism, was associated with a higher risk of T2DM [50, 51]. The possible interaction between heme iron intake and HO-1 gene polymorphisms and their combined effects in the pathogenesis of T2DM remain unknown. Second, a high correlation between intake of heme iron and red meat (the latter as a major contributor to heme iron intake that has been associated with higher risk of T2DM [34]) was found in the included study [23]. Because of a high degree of statistical collinearity, we were unable to reliably separate the independent effect of heme iron per se from other components of red meat. However, the potential link of T2DM risk to heme iron cannot be excluded because it is biologically plausible. Third, comparing the highest category of exposure with the lowest for each study cannot fully quantify the association. The dose-response trend of body iron stores in relation to T2DM risk should be evaluated in future when more studies are available. Fourth, the number of studies was not sufficient to allow us to conduct a formal meta-regression analysis for identifying potential sources of heterogeneity, and this also limited an adequate assessment of small-study effects. Fifth, most of the included studies were conducted in western populations, which limits the direct generalization of the findings. Although Asia has the largest number of patients with diabetes in the world [52, 53], and several studies in East Asian populations have suggested that T2DM were more prevalent among people with higher heme iron intakes [22, 32] and body iron stores [14, 19, 22], more studies, in particular prospective cohort studies, are still required in this population of high diabetes prevalence. Finally, although many potential confounders have been adjusted for in the included studies, we cannot completely exclude the possibilities of residual confounding from unmeasured or incompletely measured factors.